Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well molecularly targeted therapy works in treating patients
with melanoma that has spread to other parts of the body. Patients must have received or do
not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs
or other substances to identify and attack specific types of cancer cells with less harm to
normal cells. Molecularly targeted therapy works by treating patients with substances that
kill cancer cells by targeting key molecules involved in cancer cell growth.